Class Action Lawsuit Filed Against Ardelyx, Inc. Following Revenue Guidance Reductions
Pomerantz LLP has announced a class action lawsuit against Ardelyx, Inc. (NASDAQ: ARDX) regarding potential securities fraud or unlawful business practices. The legal action follows a significant drop in the company's stock price after management issued disappointing financial updates. On August 6, 2026, Ardelyx reduced its full-year revenue guidance for IBSRELA due to increased payer utilization-management processes that restricted patient access. Additionally, the company withdrew its long-term revenue guidance for XPHOZAH, citing evolving market dynamics and growth uncertainty. Following these announcements, ARDX shares fell 17.86% to close at $4.00 per share.
Tickers: $ARDX
Topics: Class Action Litigation Revenue Guidance Reduction Securities Fraud